Administration of Liposomal-Based Pde3b Gene Therapy Protects Mice Against Collagen-Induced Rheumatoid Arthritis via Modulating Macrophage Polarization
DOI: https://doi.org/10.2147/ijn.s454445
IF: 7.033
2024-05-18
International Journal of Nanomedicine
Abstract:Longmin Chen, 1 Qing Zhou, 2 Xun Fang, 1 Qianqian Xu, 2 Yuan Zou, 2 Jing Zhang 2 1 Department of Rheumatology and Immunology, the Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China; 2 Department of Respiratory and Critical Care Medicine, NHC Key Laboratory of Respiratory Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China Correspondence: Jing Zhang, Department of Respiratory and Critical Care Medicine, NHC Key Laboratory of Respiratory Disease, Tongji Hospital Research Building, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Caidian, 430100, People's Republic of China, Email Background: Rheumatoid arthritis (RA) is a chronic and systemic autoimmune disease characterized by synovial inflammation and joint destruction. Despite progress in RA therapy, it remains difficult to achieve long-term remission in RA patients. Phosphodiesterase 3B (Pde3b) is a member of the phosphohydrolyase family that are involved in many signal transduction pathways. However, its role in RA is yet to be fully addressed. Methods: Studies were conducted in arthritic DBA/1 mice, a suitable mouse strain for collagen-induced rheumatoid arthritis (CIA), to dissect the role of Pde3b in RA pathogenesis. Next, RNAi-based therapy with Pde3b siRNA-loaded liposomes was assessed in a CIA model. To study the mechanism involved, we investigated the effect of Pde3b knockdown on macrophage polarization and related signaling pathway. Results: We demonstrated that mice with CIA exhibited upregulated Pde3b expression in macrophages. Notably, intravenous administration of liposomes loaded with Pde3b siRNA promoted the macrophage anti-inflammatory program and alleviated CIA in mice, as indicated by the reduced inflammatory response, synoviocyte infiltration, and bone and cartilage erosion. Mechanistic study revealed that depletion of Pde3b increased cAMP levels, by which it enhanced PKA-CREB-C/EBPβ pathway to transcribe the expression of anti-inflammatory program-related genes. Conclusion: Our results support that Pde3b is involved in the pathogenesis of RA, and Pde3b siRNA-loaded liposomes might serve as a promising therapeutic approach against RA. Keywords: rheumatoid arthritis, Pde3b, liposomes, macrophages Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease affecting ~0.5–1.0% of the population worldwide. 1 RA is characterized by articular inflammation, often with accumulating joint damage and irreversible disability if insufficiently treated. Currently, RA is still regarded as an incurable disease, and glucocorticoids (GCs), non-steroidal anti-inflammatory drugs (NSAIDs), and disease-modifying anti-rheumatic drugs (DMARDs) are the most commonly used medications in clinic. 2 Although they could relieve symptoms and delay arthritis progression, frequent administration and high dosage are often needed to achieve optimal disease control, which inevitably result in poor compliance and untoward adverse effects. 2,3 Over the past two decades, we have witnessed the evolution and approval of a variety of biological agents, ie, antibodies against tumor necrosis factor (TNF) and interleukin (IL)-6 receptor. However, biologic agents are expensive, and approximately 30–40% of patients do not respond well, accompanied with increased risk of infections. 4,5 Thus, novel therapeutic strategies for RA are urgently needed. The pathogenesis of RA involves a broad range of inflammatory processes, including dysregulated cytokine production and complicated crosstalk among inflammatory cells. 6 Among these cells, macrophages play a crucial role in shifting synovial inflammation towards a pathological state versus an adaptive response. Macrophages are classified into two subtypes, classically activated macrophages (pro-inflammatory macrophages) and alternatively activated macrophages (anti-inflammatory macrophages). 7,8 In the healthy joint, macrophages typically express anti-inflammatory markers, including arginase 1 (Arg1) and the mannose receptor CD206, and produce immune-regulatory cytokines such as IL-10, IL-13, and transforming growth factor (TGF)-β, which contribute to the maintenance of tissue homeostasis. During RA, however, pro-inflammatory macrophages that secret inflammatory mediators such as IL-1β, IL-6, and TNF-α accumulate in the swollen inflamed synovial tissue and promote tissue destruction and bone erosion. 9 In this respect, shifting synovial macrophages -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology